FDA Center for Drug Evaluation & Research Issues Warning Letter to K.C. Pharmaceuticals
August 19, 2026
August 19, 2026
WASHINGTON, Aug. 19 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to K.C. Pharmaceuticals Inc. from its Center for Drug Evaluation and Research:
* * *
Recipient: Ms. Ratnawati Li, Chief Executive Officer, K.C. Pharmaceuticals, Inc., 3420 Pomona Blvd., Pomona, CA 91768, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
Warning Letter . . .
* * *
Recipient: Ms. Ratnawati Li, Chief Executive Officer, K.C. Pharmaceuticals, Inc., 3420 Pomona Blvd., Pomona, CA 91768, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
Warning Letter . . .